The novel human MOST-1 (C8orf17) gene exhibits tissue specific expression, maps to chromosome 8q24.2, and is overexpressed/amplified in high grade cancers of the breast and prostate

被引:8
作者
Tan, JMM
Tock, EPC
Chow, VTK
机构
[1] Natl Univ Singapore, Human Genome Lab, Dept Microbiol, Fac Med, Singapore 117597, Singapore
[2] Natl Univ Singapore Hosp, Dept Pathol, Singapore 119074, Singapore
来源
JOURNAL OF CLINICAL PATHOLOGY-MOLECULAR PATHOLOGY | 2003年 / 56卷 / 02期
关键词
D O I
10.1136/mp.56.2.109
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Aims: To elucidate genes that participate in the process of oncogenesis, primers based on the E6 genes of genital human papillomaviruses (HPVs) were used to amplify potential expressed sequence tags (ESTs) from the MOLT-4 T lymphoblastic leukaemia cell line. Methods: Using the polymerase chain reaction (PCR) with human papillomavirus E6 gene primers, an EST from the MOLT-4 T lymphoblastic leukaemia cell line was amplified. Via rapid amplification of cDNA ends (RACE) and cycle sequencing from MOLT-4 and fetal lung cDNA libraries, overlapping cDNAs of 2786 bp and 2054 bp of the corresponding novel human intronless gene designated MOST-1 (for MOLT-4 sequence tag-1) were characterised and assigned the symbol C8orf17 by the HUGO Nomenclature Committee. Results: Both cDNAs contained a potential open reading frame (ORF) of 297 bp incorporating a methionine codon with an ideal Kozak consensus sequence for translation initiation, and encoding a putative hydrophilic polypeptide of 99 amino acids. Although reverse transcription PCR (RT-PCR) demonstrated MOST-1 expression in all 19 cancer and two normal cell lines tested, differential expression was seen in only nine of 16 normal tissues tested (heart, kidney, liver, pancreas, small intestine, ovary, testis, prostate, and thymus). A 388 bp fragment was amplified from the NS-1 mouse myeloma cell line, the sequence of which was identical to that within the MOST-1 ORF. The MOST-1 gene was mapped by fluorescent in situ hybridisation to chromosome 8q24.2, a region amplified in many breast cancers and prostate cancers, which is also the candidate site of potential oncogene(s) other than c-myc located at 8q24.1. Analysis of paired biopsies of invasive ductal breast cancer and adjacent normal tissue by semiquantitative and real time RT-PCR revealed average tumour to normal ratios of MOST-1 expression that were two times greater in grade 3 cancers than in grade 1 and 2 cancers. Quantitative real time PCR of archival prostatic biopsies displayed MOST-1 DNA values that were 9.9, 7.5, 4.2, and 1.4 times higher in high grade carcinomas, intermediate grade carcinomas, low grade carcinomas, and benign hyperplasias, respectively, than in normal samples. Conclusions: These data suggest a role for MOST-1 in cellular differentiation, proliferation, and carcinogenesis.
引用
收藏
页码:109 / 115
页数:7
相关论文
共 47 条
[1]  
AbdelMageed AB, 1997, CANCER GENE THER, V4, P199
[2]   COMPLEMENTARY-DNA SEQUENCING - EXPRESSED SEQUENCE TAGS AND HUMAN GENOME PROJECT [J].
ADAMS, MD ;
KELLEY, JM ;
GOCAYNE, JD ;
DUBNICK, M ;
POLYMEROPOULOS, MH ;
XIAO, H ;
MERRIL, CR ;
WU, A ;
OLDE, B ;
MORENO, RF ;
KERLAVAGE, AR ;
MCCOMBIE, WR ;
VENTER, JC .
SCIENCE, 1991, 252 (5013) :1651-1656
[3]  
AKASHI M, 1994, BLOOD, V83, P3182
[4]   HISTOLOGICAL GRADING AND PROGNOSIS IN BREAST CANCER - A STUDY OF 1409 CASES OF WHICH 359 HAVE BEEN FOLLOWED FOR 15 YEARS [J].
BLOOM, HJG ;
RICHARDSON, WW .
BRITISH JOURNAL OF CANCER, 1957, 11 (03) :359-&
[5]  
Chang GTG, 1999, INT J CANCER, V83, P506, DOI 10.1002/(SICI)1097-0215(19991112)83:4<506::AID-IJC12>3.0.CO
[6]  
2-0
[7]   Complete nucleotide sequence, genomic organization and phylogenetic analysis of a novel genital human papillomavirus type, HLT474-S [J].
Chow, VTK ;
Leong, PWF .
JOURNAL OF GENERAL VIROLOGY, 1999, 80 :2923-2929
[8]  
Chow VTK, 2000, PATHOLOGY, V32, P204, DOI 10.1080/713688930
[9]   The human DENN gene:: genomic organization, alternative splicing, and localization to chromosome 11p11.21-p11.22 [J].
Chow, VTK ;
Lim, KM ;
Lim, D .
GENOME, 1998, 41 (04) :543-552
[10]  
De Angelis PM, 1999, BRIT J CANCER, V80, P526